<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6C3C4678-08A0-41A6-AB25-6733CAED0848"><gtr:id>6C3C4678-08A0-41A6-AB25-6733CAED0848</gtr:id><gtr:name>Micregen Ltd</gtr:name><gtr:address><gtr:line1>Biohub At Alderley Park,Alderley Park</gtr:line1><gtr:city>Alderley Edge</gtr:city><gtr:postCode>SK10 4TG</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6C3C4678-08A0-41A6-AB25-6733CAED0848" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>6C3C4678-08A0-41A6-AB25-6733CAED0848</gtr:id><gtr:name>Micregen Ltd</gtr:name><gtr:address><gtr:line1>Biohub At Alderley Park,Alderley Park</gtr:line1><gtr:city>Alderley Edge</gtr:city><gtr:postCode>SK10 4TG</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>373679.0</gtr:offerGrant><gtr:projectCost>533827.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C1CBEF0C-544B-4960-A923-6E02A1DCBD51"><gtr:id>C1CBEF0C-544B-4960-A923-6E02A1DCBD51</gtr:id><gtr:firstName>Barry</gtr:firstName><gtr:surname>Sharples</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=133320"><gtr:id>BB2749D0-3637-47BB-9772-94284484CDD1</gtr:id><gtr:title>MICREGEN ? A novel therapeutic for treating necrotising enterocolitis (NEC)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>133320</gtr:grantReference><gtr:abstractText>&amp;quot;Necrotising Enterocolitis is a rare but severely debilitating and often fatal (40% survival with surgery) gastrointestinal disorder occurring in new-born children, affecting 3 in 10,000 babies. It is particularly prevalent (around 3 in 1000) in preterm babies and those born at under 800g, with up to 10% developing NEC. There is currently no cure for NEC and this enigmatic disease remains a challenge for neonatologists around the world as its definite cause has yet to be determined.

Micregen have created an innovative new therapeutic centred on cell free therapy. Significant efficacy from injecting patients will be far less invasive, improve recovery time, and be much better for them in the long term, compared to surgery. For parents and family members of neonates with NEC, this will prove far less traumatic. Cost savings of \\\&amp;gt;&amp;pound;300m in 5 years are expected for the Health Service by saving surgery costs, secondary conditions and reducing the time spent by patients in ICU. The long-term costs to the patient, parents, family members and the Health Service are expected to be significantly reduced, compared to the life-long medical treatment required for those patients that survive today who currently experience a poor quality of life.

The therapeutic is expected to decrease the mortality of an NE patient from 18% to 9%, and for patients with pan-intestinal severity from 86% to 21%. The long-term costs to the Health Service are expected to be significantly reduced, compared to the life-long medical treatment required for those patients that survive today, who currently experience a poor quality of life and social exclusion. Bridging, or off label use of MRG1061 for other inflammatory indications could be utilised by any clinic. Being an injectable, the treatment is non-invasive, fast and permanent, saving clinics significant time and costs.&amp;quot;</gtr:abstractText><gtr:fund><gtr:end>2019-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2018-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>373679</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">133320</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>